Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$2.18.

  • BioXcel Therapeutics' EPS (Basic) rose 5766.99% to -$2.18 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.04, marking a year-over-year increase of 9215.75%. This contributed to the annual value of -$31.47 for FY2024, which is 6799.73% up from last year.
  • Per BioXcel Therapeutics' latest filing, its EPS (Basic) stood at -$2.18 for Q3 2025, which was up 5766.99% from -$2.45 recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year EPS (Basic) high stood at -$1.12 for Q1 2022, and its period low was -$92.93 during Q4 2023.
  • For the 4-year period, BioXcel Therapeutics' EPS (Basic) averaged around -$9.22, with its median value being -$1.96 (2022).
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 464132.65% in 2023, then surged by 9399.05% in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' EPS (Basic) stood at -$1.96 in 2022, then plummeted by 4641.33% to -$92.93 in 2023, then soared by 93.99% to -$5.58 in 2024, then soared by 60.96% to -$2.18 in 2025.
  • Its last three reported values are -$2.18 in Q3 2025, -$2.45 for Q2 2025, and -$1.5 during Q1 2025.